;PMID: 3091830
;source_file_662.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..85] = [t:41..85]
;2)sentence:[e:86..195] = [t:86..195]
;3)section:[e:199..244] = [t:199..244]
;4)sentence:[e:248..412] = [t:248..412]
;5)sentence:[e:413..549] = [t:413..549]
;6)sentence:[e:550..697] = [t:550..697]
;7)sentence:[e:698..925] = [t:698..925]
;8)sentence:[e:926..1014] = [t:926..1014]
;9)section:[e:1018..1062] = [t:1018..1062]

;section 0 Span:0..35
;J Med Chem. 1986 Sep;29(9):1643-50.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..5] Med) (NNP:[6..10] Chem) (.:[10..11] .)
        (CD:[12..16] 1986) (CC:[17..22] Sep;2) (CD:[22..23] 9)
        (NN:[23..24] -LRB-) (NN:[24..25] 9) (NN:[25..26] -RRB-) (::[26..27] :)
        (CD:[27..30] 164) (CD:[30..34] 3-50) (.:[34..35] .)))

;sentence 1 Span:41..85
;Selective thromboxane synthetase inhibitors.
;[51..73]:cyp450:"thromboxane synthetase"
;[74..84]:substance:"inhibitors"
(SENT
  (NP-HLN (JJ:[41..50] Selective)
    (NML (NN:[51..62] thromboxane) (NN:[63..73] synthetase))
    (NNS:[74..84] inhibitors) (.:[84..85] .)))

;sentence 2 Span:86..195
;4. 2-(1H-imidazol-1-ylmethyl)  carboxylic acids of benzo[b]furan,
;benzo[b]thiophene, indole, and naphthalene.
;[89..133]:substance:"2-(1H-imidazol-1-ylmethyl)  carboxylic acids"
;[137..150]:substance:"benzo[b]furan"
;[152..169]:substance:"benzo[b]thiophene"
;[171..177]:substance:"indole"
;[183..194]:substance:"naphthalene"
(SENT
  (NP-HLN
    (NP (LS:[86..88] 4.)
       (NN:[89..115] 2--LRB-1H-imidazol-1-ylmethyl-RRB-)
       (JJ:[117..127] carboxylic) (NNS:[128..133] acids))
    (PP (IN:[134..136] of)
      (NP (NN:[137..150] benzo-LSB-b-RSB-furan) (,:[150..151] ,)
          (NN:[152..169] benzo-LSB-b-RSB-thiophene) (,:[169..170] ,)
          (NN:[171..177] indole) (,:[177..178] ,) (CC:[179..182] and)
          (NN:[183..194] naphthalene)))
    (.:[194..195] .)))

;section 3 Span:199..244
;Cross PE, Dickinson RP, Parry MJ, Randall MJ.
(SEC
  (FRAG (NNP:[199..204] Cross) (NNP:[205..207] PE) (,:[207..208] ,)
        (NNP:[209..218] Dickinson) (NNP:[219..221] RP) (,:[221..222] ,)
        (NNP:[223..228] Parry) (NNP:[229..231] MJ) (,:[231..232] ,)
        (NNP:[233..240] Randall) (NNP:[241..244] MJ.)))

;sentence 4 Span:248..412
;The preparation of a series of 2-(1H-imidazol-1-ylmethyl)-substituted
;carboxylic  acids of benzo[b]furan, benzo-[b]thiophene, indole, and
;naphthalene is  described.
;[279..335]:substance:"2-(1H-imidazol-1-ylmethyl)-substituted carboxylic 
;acids"
;[339..352]:substance:"benzo[b]furan"
;[354..372]:substance:"benzo-[b]thiophene"
;[374..380]:substance:"indole"
;[386..397]:substance:"naphthalene"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[248..251] The) (NN:[252..263] preparation))
      (PP (IN:[264..266] of)
        (NP
          (NP (DT:[267..268] a) (NN:[269..275] series))
          (PP (IN:[276..278] of)
            (NP
              (NP
                (ADJP (NN:[279..305] 2--LRB-1H-imidazol-1-ylmethyl-RRB-)
                      (HYPH:[305..306] -) (VBN:[306..317] substituted))
                (JJ:[318..328] carboxylic) (NNS:[330..335] acids))
              (PP (IN:[336..338] of)
                (NP (NN:[339..352] benzo-LSB-b-RSB-furan) (,:[352..353] ,)
                    (NN:[354..372] benzo--LSB-b-RSB-thiophene) (,:[372..373] ,)
                    (NN:[374..380] indole) (,:[380..381] ,) (CC:[382..385] and)
                    (NN:[386..397] naphthalene))))))))
    (VP (VBZ:[398..400] is)
      (VP (VBN:[402..411] described)
        (NP-1 (-NONE-:[411..411] *))))
    (.:[411..412] .)))

;sentence 5 Span:413..549
;All compounds showed a similar level of activity as TxA2 synthetase 
;inhibitors in vitro, having IC50 values between 1 and 7 X 10(-8) M.
;[417..426]:substance:"compounds"
;[465..480]:cyp450:"TxA2 synthetase"
;[482..492]:substance:"inhibitors"
;[510..514]:quantitative-name:"IC50"
;[530..546]:quantitative-value:"1 and 7 X 10(-8)"
;[547..548]:quantitative-units:"M"
(SENT
  (S
    (NP-SBJ (DT:[413..416] All) (NNS:[417..426] compounds))
    (VP (VBD:[427..433] showed)
      (NP
        (NP (DT:[434..435] a) (JJ:[436..443] similar) (NN:[444..449] level))
        (PP (IN:[450..452] of)
          (NP (NN:[453..461] activity)))
        (PP (IN:[462..464] as)
          (NP
             (NN:[465..469] TxA2) (NN:[470..480] synthetase)
            (NNS:[482..492] inhibitors))))
      (ADVP (FW:[493..495] in) (FW:[496..501] vitro))
      (,:[501..502] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[502..502] *))
        (VP (VBG:[503..509] having)
          (NP
            (NP (NN:[510..514] IC50) (NNS:[515..521] values))
            (PP (IN:[522..529] between)
              (NP
                (QP (CD:[530..531] 1) (CC:[532..535] and) (CD:[536..537] 7)
                    (SYM:[538..539] X) (CD:[540..546] 10-LRB--8-RRB-))
                (NN:[547..548] M)))))))
    (.:[548..549] .)))

;sentence 6 Span:550..697
;In the cases  examined, compounds had, at most, only negligible activity
;against PGI2  synthetase, cyclooxygenase, and steroid 11 beta-hydroxylase.
;[574..583]:substance:"compounds"
;[631..647]:substance:"PGI2  synthetase"
;[649..663]:substance:"cyclooxygenase"
;[669..696]:cyp450:"steroid 11 beta-hydroxylase"
(SENT
  (S
    (PP (IN:[550..552] In)
      (NP
        (NP (DT:[553..556] the) (NNS:[557..562] cases))
        (VP (VBN:[564..572] examined)
          (NP (-NONE-:[572..572] *)))))
    (,:[572..573] ,)
    (NP-SBJ (NNS:[574..583] compounds))
    (VP (VBD:[584..587] had) (,:[587..588] ,)
      (ADVP (IN:[589..591] at) (RBS:[592..596] most))
      (,:[596..597] ,)
      (NP
        (NP
          (ADJP (RB:[598..602] only) (JJ:[603..613] negligible))
          (NN:[614..622] activity))
        (PP (IN:[623..630] against)
          (NP
            (NP (NN:[631..635] PGI2) (NN:[637..647] synthetase))
            (,:[647..648] ,)
            (NP (NN:[649..663] cyclooxygenase))
            (,:[663..664] ,) (CC:[665..668] and)
            (NP (JJ:[669..676] steroid) (CD:[677..679] 11)
                (NN:[680..696] beta-hydroxylase))))))
    (.:[696..697] .)))

;sentence 7 Span:698..925
;The  benzo[b]thiophenes generally showed the greatest potency in vivo, and
;compounds  72, 73, and 75 caused almost complete inhibition of thromboxane
;production for 6  h after oral administration of 0.5 mg/kg to conscious
;dogs.
;[703..721]:substance:"benzo[b]thiophenes"
;[773..782]:substance:"compounds"
;[784..786]:substance:"72"
;[788..790]:substance:"73"
;[796..798]:substance:"75"
;[836..847]:substance:"thromboxane"
;[863..864]:quantitative-value:"6"
;[866..867]:quantitative-units:"h"
;[897..900]:quantitative-value:"0.5"
;[901..906]:quantitative-units:"mg/kg"
(SENT
  (S
    (S
      (NP-SBJ (DT:[698..701] The) (NNS:[703..721] benzo-LSB-b-RSB-thiophenes))
      (ADVP (RB:[722..731] generally))
      (VP (VBD:[732..738] showed)
        (NP (DT:[739..742] the) (JJS:[743..751] greatest)
            (NN:[752..759] potency))
        (ADVP (FW:[760..762] in) (FW:[763..767] vivo))))
    (,:[767..768] ,) (CC:[769..772] and)
    (S
      (NP-SBJ
        (NP
          (NML-1 (NNS:[773..782] compounds))
          (CD:[784..786] 72))
        (,:[786..787] ,)
        (NP
          (NML-1 (-NONE-:[787..787] *P*))
          (CD:[788..790] 73))
        (,:[790..791] ,) (CC:[792..795] and)
        (NP
          (NML-1 (-NONE-:[795..795] *P*))
          (CD:[796..798] 75)))
      (VP (VBD:[799..805] caused)
        (NP
          (NP
            (ADJP (RB:[806..812] almost) (JJ:[813..821] complete))
            (NN:[822..832] inhibition))
          (PP (IN:[833..835] of)
            (NP (NN:[836..847] thromboxane) (NN:[848..858] production))))
        (PP-TMP (IN:[859..862] for)
          (NP (CD:[863..864] 6) (NN:[866..867] h)))
        (PP-TMP (IN:[868..873] after)
          (NP
            (NP (JJ:[874..878] oral) (NN:[879..893] administration))
            (PP (IN:[894..896] of)
              (NP
                (NP (CD:[897..900] 0.5) (NN:[901..903] mg))
                (PP (SYM:[903..904] /)
                  (NP (NN:[904..906] kg)))))
            (PP (TO:[907..909] to)
              (NP (JJ:[910..919] conscious) (NNS:[920..924] dogs)))))))
    (.:[924..925] .)))

;sentence 8 Span:926..1014
;In the case of 73  and 75, thromboxane production was still inhibited by 80%
;after 24 h.
;[941..943]:substance:"73"
;[949..951]:substance:"75"
;[953..964]:substance:"thromboxane"
;[999..1002]:quantitative-value:"80%"
;[1009..1011]:quantitative-value:"24"
;[1012..1013]:quantitative-units:"h"
(SENT
  (S
    (PP (IN:[926..928] In)
      (NP
        (NP (DT:[929..932] the) (NN:[933..937] case))
        (PP (IN:[938..940] of)
          (NP (CD:[941..943] 73) (CC:[945..948] and) (CD:[949..951] 75)))))
    (,:[951..952] ,)
    (NP-SBJ-1 (NN:[953..964] thromboxane) (NN:[965..975] production))
    (VP (VBD:[976..979] was)
      (ADVP-TMP (RB:[980..985] still))
      (VP (VBN:[986..995] inhibited)
        (NP-1 (-NONE-:[995..995] *))
        (PP-EXT (IN:[996..998] by)
          (NP (CD:[999..1001] 80) (NN:[1001..1002] %)))
        (PP-TMP (IN:[1003..1008] after)
          (NP (CD:[1009..1011] 24) (NN:[1012..1013] h)))))
    (.:[1013..1014] .)))

;section 9 Span:1018..1062
;PMID: 3091830 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1018..1022] PMID) (::[1022..1023] :) (CD:[1024..1031] 3091830)
        (NN:[1032..1033] -LSB-) (NNP:[1033..1039] PubMed) (::[1040..1041] -)
        (NN:[1042..1049] indexed) (IN:[1050..1053] for)
        (NNP:[1054..1062] MEDLINE-RSB-)))
